| scholarly article | Q13442814 |
| P50 | author | Emmanuel Curis | Q39066404 |
| P2093 | author name string | Vincent Jullien | |
| Dominique Salmon | |||
| Laure Gatin | |||
| Philippe Anract | |||
| Philippe Morand | |||
| Denis Archambeau | |||
| Antoine Babinet | |||
| Jean-Claude Nguyen Van | |||
| Valérie Dumaine | |||
| Vincent Pestre | |||
| Luc Eyrolle | |||
| Matthieu Karoubi | |||
| Nicolas Pinar | |||
| P2860 | cites work | Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh [...] | Q24643277 |
| Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate | Q28359157 | ||
| Simultaneous inference in general parametric models | Q29619454 | ||
| Antimicrobial treatment of chronic osteomyelitis. | Q33547660 | ||
| Continuous clindamycin infusion, an innovative approach to treating bone and joint infections | Q33559008 | ||
| Pharmacokinetics of clindamycin in pregnant women in the peripartum period. | Q33826411 | ||
| Antibiotic treatment of gram-positive bone and joint infections | Q34317423 | ||
| Concentration of clindamycin in human bone | Q34939078 | ||
| Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. | Q35126312 | ||
| Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis | Q35133942 | ||
| Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus | Q35141244 | ||
| Pharmacokinetic interactions with rifampicin : clinical relevance | Q35185727 | ||
| Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens | Q35565851 | ||
| Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy | Q36505327 | ||
| Polymicrobial prosthetic joint infections: risk factors and outcome | Q36657727 | ||
| Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs | Q37247443 | ||
| Risk factors for treatment failure in patients with prosthetic joint infections | Q38480446 | ||
| Comparative penetration of metronidazole, clindamycin, chloramphenicol, cefoxitin, ticarcillin, and moxalactam into bone | Q39856824 | ||
| Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. | Q39866037 | ||
| Clindamycin in bone and joint infections | Q40810527 | ||
| Bacteriostatic and Bactericidal Activities of Various Antibiotics Against Bacteroides fragilis | Q41028765 | ||
| A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure | Q41217269 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Penetration of clindamycin into synovial fluid | Q43612256 | ||
| In vitro metabolism of clindamycin in human liver and intestinal microsomes | Q44483232 | ||
| Clindamycin treatment of osteomyelitis and septic arthritis in children | Q44563327 | ||
| Treatment of osteoarticular infections with clindamycin in adults | Q46417724 | ||
| Evaluation of gender in the oral pharmacokinetics of clindamycin in humans | Q46486317 | ||
| Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore | Q58033538 | ||
| The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin | Q66845270 | ||
| Antibiotic bone penetration. Concentrations of methicillin and clindamycin phosphate in human bone taken during total hip replacement | Q67243971 | ||
| Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects | Q67436611 | ||
| Antibacterial activity of clindamycin and lincomycin in human bone | Q67576896 | ||
| Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis | Q68178250 | ||
| Clindamycin Levels in Various Body Tissues and Fluids | Q68950778 | ||
| Tissue penetration of clindamycin in diabetic foot infections | Q70769438 | ||
| Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human | Q71731673 | ||
| Outcome of group B streptococcal prosthetic hip infections compared to that of other bacterial infections | Q84068001 | ||
| Efficacy of a combined oral clindamycin?rifampicin regimen for therapy of staphylococcal osteoarticular infections | Q84942620 | ||
| P433 | issue | 4 | |
| P921 | main subject | rifampicin | Q422652 |
| pharmacokinetics | Q323936 | ||
| clindamycin | Q422273 | ||
| P304 | page(s) | 473-481 | |
| P577 | publication date | 2015-04-03 | |
| P1433 | published in | Infection | Q15710156 |
| P1476 | title | Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections | |
| P478 | volume | 43 |
| Q38667207 | An Update on Medical Treatment Options for Hidradenitis Suppurativa |
| Q36361173 | Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. |
| Q40061078 | Efficacy and safety of clindamycin-based treatment for bone and joint infections: a cohort study |
| Q37084442 | Treatment of prosthetic joint infections due to Propionibacterium. Similar results in 60 patients treated with and without rifampicin |
Search more.